Geneva, Switzerland and Boston, MA – May 8, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization…
Category: Press release
The press releases from ObsEva
ObsEva SA Reports Consistent Long-Term Findings from Phase 2b EDELWEISS trial of Linzagolix for Endometriosis-Associated Pain
Geneva, Switzerland and Boston, MA – May 3, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization…
ObsEva SA to Hold First Quarter 2019 Financial Results and Business Update Call on May 9, 2019
Geneva, Switzerland and Boston, MA –May 1, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and…
ObsEva SA Reports Further Infant Follow-up Data from IMPLANT2 Trial Echoing Favorable Safety Profile of Nolasiban in IVF
Geneva, Switzerland and Boston, MA – April 29 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of…
ObsEva SA to Participate in Upcoming Investor Conferences
Geneva, Switzerland and Boston, MA – April 1, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization…
Publication of ObsEva SA Invitation to 2019 Annual General Meeting of Shareholders
Geneva, Switzerland and Boston, MA – March 29, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization…
Nolasiban Set to Revolutionise Fertility: Interview in ‘The Times’ with ObsEva CEO, Ernest Loumaye
ObsEva SA to Present OBE022 Clinical Data for Treatment of Pre-term labor (PTL) at the SRI 66th Annual Scientific Meeting, March 12 -16, 2019
Geneva, Switzerland and Boston – March 13, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of…
ObsEva Reports Fourth Quarter and Full Year 2018 Financial Results, Provides Business Update
Major 2018 Accomplishments Driven by Positive Clinical Trial Results –Significant increase in rates of pregnancy and live birth (up to…
ObsEva SA to Hold Fourth Quarter and Full Year 2018 Financial Results and Business Update Call on March 5, 2019
Geneva, Switzerland and Boston, MA –February 27, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and…